2篇
您的检索式：作者名="Michele Massari"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multiplication and division of the orbital angular momentum of light with diffractive transformation optics显示文摘We present a method to efficiently multiply or divide the orbital angular momentum(OAM)of light beams using a sequence of two optical elements.The key element is represented by an optical transformation mapping the azimuthal phase gradient of the input OAM beam onto a circular sector.By combining multiple circular-sector transformations into a single optical element,it is possible to multiply the value of the input OAM state by splitting and mapping the phase onto complementary circular sectors.Conversely,by combining multiple inverse transformations,the division of the initial OAM value is achievable by mapping distinct complementary circular sectors of the input beam into an equal number of circular phase gradients.Optical elements have been fabricated in the form of phase-only diffractive optics with high-resolution electron-beam lithography.Optical tests confirm the capability of the multiplier optics to perform integer multiplication of the input OAM,whereas the designed dividers are demonstrated to correctly split up the input beam into a complementary set of OAM beams.These elements can find applications for the multiplicative generation of higher-order OAM modes,optical information processing based on OAM beam transmission,and optical routing/switching in telecom. | Gianluca Ruffato Michele Massari Filippo Romanato | 2019 | Light(Science & Applications)2019，8，1： | 8 |
| 2 | “Targeting” renal cell carcinoma patients with “targeted” agents: Are we there yet?显示文摘The rapid approval of several novel agents, targeting the vascular endothelial growth factor or mammalian target of rapamycin pathways(sunitinib, pazopanib, sorafenib, axitinib, bevacizumab, everolimus, temsirolimus) has given to metastatic renal cell carcinoma(m RCC) patients and their treating physicians many new and effective therapeutic options. The treatment paradigm for these patients is rapidly evolving, with future studies needed to defi ne the optimal sequencing of these new agents. Despite progresses, no validated biomarkers able to predict clinical outcome or useful to guide patient selection for treatment are currently available. Recent studies have suggested that some biomarkers, including cytokines, circulating proangio-genic factors, markers of hypoxia or targets of signaling pathways are potentially promising prognostic or predictive factors in m RCC. We present an overview of the most recent developments in identifying biomarkers for targeted therapies in advanced RCC. | Francesca Maines Sara Pilotto Michele Milella Francesco Massari Vanja Vaccaro Alessandra Felici Emilio Bria Giampaolo Tortora | 2014 | World Journal of Clinical Urology2014，3，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员